Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Position Lowered by State Street Corp

State Street Corp cut its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 7.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 728,770 shares of the specialty pharmaceutical company’s stock after selling 55,263 shares during the period. State Street Corp owned 1.22% of Jazz Pharmaceuticals PLC worth $105,779,000 as of its most recent filing with the SEC.

A number of other hedge funds have also added to or reduced their stakes in JAZZ. OppenheimerFunds Inc. increased its stake in shares of Jazz Pharmaceuticals PLC by 54.1% in the first quarter. OppenheimerFunds Inc. now owns 150,840 shares of the specialty pharmaceutical company’s stock worth $21,891,000 after buying an additional 52,960 shares in the last quarter. UBS Group AG increased its stake in shares of Jazz Pharmaceuticals PLC by 17.3% in the first quarter. UBS Group AG now owns 338,433 shares of the specialty pharmaceutical company’s stock worth $49,116,000 after buying an additional 50,032 shares in the last quarter. Credit Agricole S A increased its stake in shares of Jazz Pharmaceuticals PLC by 24.9% in the fourth quarter. Credit Agricole S A now owns 10,935 shares of the specialty pharmaceutical company’s stock worth $1,193,000 after buying an additional 2,181 shares in the last quarter. Pinnacle Associates Ltd. purchased a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter worth about $235,000. Finally, TIAA CREF Investment Management LLC increased its stake in shares of Jazz Pharmaceuticals PLC by 178.2% in the first quarter. TIAA CREF Investment Management LLC now owns 663,548 shares of the specialty pharmaceutical company’s stock worth $96,301,000 after buying an additional 425,042 shares in the last quarter. Institutional investors own 86.14% of the company’s stock.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded up 0.77% on Friday, reaching $155.60. 366,705 shares of the company’s stock were exchanged. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The stock’s 50 day moving average price is $155.48 and its 200 day moving average price is $145.64. The firm has a market capitalization of $9.34 billion, a price-to-earnings ratio of 23.51 and a beta of 1.10.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.42 by $0.01. The company had revenue of $376.10 million for the quarter, compared to analyst estimates of $376.58 million. Jazz Pharmaceuticals PLC had a return on equity of 24.65% and a net margin of 26.28%. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $2.26 EPS. On average, analysts expect that Jazz Pharmaceuticals PLC will post $11.02 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally published by BBNS and is the sole property of of BBNS. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/jazz-pharmaceuticals-plc-nasdaqjazz-stake-lowered-by-state-street-corp-updated-updated-updated/1180099.html.

A number of research firms recently weighed in on JAZZ. Zacks Investment Research cut shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Royal Bank Of Canada set a $210.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Tuesday, June 27th. Cantor Fitzgerald reissued a “buy” rating and issued a $197.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, June 27th. Cowen and Company reissued an “outperform” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, May 10th. Finally, Leerink Swann set a $179.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Thursday, April 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have assigned a buy rating to the company. Jazz Pharmaceuticals PLC presently has a consensus rating of “Buy” and a consensus price target of $182.56.

In other Jazz Pharmaceuticals PLC news, CEO Bruce C. Cozadd sold 30,000 shares of the business’s stock in a transaction dated Thursday, May 11th. The stock was sold at an average price of $153.47, for a total transaction of $4,604,100.00. Following the completion of the sale, the chief executive officer now directly owns 296,418 shares of the company’s stock, valued at approximately $45,491,270.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $152.98, for a total value of $30,596.00. Following the completion of the sale, the executive vice president now directly owns 22,623 shares of the company’s stock, valued at $3,460,866.54. The disclosure for this sale can be found here. Insiders have sold a total of 43,100 shares of company stock valued at $6,645,820 over the last three months. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with our FREE daily email newsletter.

 


Latest News

Albert Pujols New Home Run Leader for Foreign-Born Players
Albert Pujols New Home Run Leader for Foreign-Born Players
Los Angeles Dodgers Alex Wood Has Shoulder Inflammation
Los Angeles Dodgers Alex Wood Has Shoulder Inflammation
Blues Jays Ready to Take Flight
Blues Jays Ready to Take Flight
Umpires Ending Protest Over Incident With Ian Kinsler
Umpires Ending Protest Over Incident With Ian Kinsler
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer


Leave a Reply

 
© 2006-2017 BBNS.